Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 56

Publication Record

Connections

NF-κB gene signature predicts prostate cancer progression.
Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ
(2014) Cancer Res 74: 2763-72
MeSH Terms: Animals, Carcinogenesis, Cell Line, Tumor, Disease Models, Animal, Disease Progression, Gene Expression Profiling, Gene Regulatory Networks, Humans, I-kappa B Proteins, Male, Mice, Mice, Transgenic, NF-KappaB Inhibitor alpha, NF-kappa B, Neoplasm Metastasis, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Signal Transduction
Show Abstract · Added May 27, 2014
In many patients with prostate cancer, the cancer will be recurrent and eventually progress to lethal metastatic disease after primary treatment, such as surgery or radiation therapy. Therefore, it would be beneficial to better predict which patients with early-stage prostate cancer would progress or recur after primary definitive treatment. In addition, many studies indicate that activation of NF-κB signaling correlates with prostate cancer progression; however, the precise underlying mechanism is not fully understood. Our studies show that activation of NF-κB signaling via deletion of one allele of its inhibitor, IκBα, did not induce prostatic tumorigenesis in our mouse model. However, activation of NF-κB signaling did increase the rate of tumor progression in the Hi-Myc mouse prostate cancer model when compared with Hi-Myc alone. Using the nonmalignant NF-κB-activated androgen-depleted mouse prostate, a NF-κB-activated recurrence predictor 21 (NARP21) gene signature was generated. The NARP21 signature successfully predicted disease-specific survival and distant metastases-free survival in patients with prostate cancer. This transgenic mouse model-derived gene signature provides a useful and unique molecular profile for human prostate cancer prognosis, which could be used on a prostatic biopsy to predict indolent versus aggressive behavior of the cancer after surgery.
©2014 American Association for Cancer Research.
3 Communities
5 Members
0 Resources
18 MeSH Terms
Genetic polymorphism of NFKB1 and NFKBIA genes and liver cancer risk: a nested case-control study in Shanghai, China.
Gao J, Xu HL, Gao S, Zhang W, Tan YT, Rothman N, Purdue M, Gao YT, Zheng W, Shu XO, Xiang YB
(2014) BMJ Open 4: e004427
MeSH Terms: Adult, Aged, Asian Continental Ancestry Group, Case-Control Studies, China, Female, Genetic Predisposition to Disease, Haplotypes, Humans, I-kappa B Proteins, Liver Neoplasms, Male, Middle Aged, NF-KappaB Inhibitor alpha, NF-kappa B p50 Subunit, Polymorphism, Single Nucleotide
Show Abstract · Added March 10, 2014
OBJECTIVES - Genetic variations of nuclear factor-κB (NF-κB) signalling pathway were found to be associated with inflammatory diseases and several malignancies. However, little is known about NF-κB pathway gene polymorphisms and susceptibility of liver cancer. The aim of this study was to investigate whether genetic variants of NFKB1 and NFKBIA were associated with risk of liver cancer in a Chinese population.
DESIGN - The study was designed as a nested case-control study within two prospective cohorts (the Shanghai Women's Health Study, SWHS, 1996-2000 and the Shanghai Men's Health Study, SMHS, 2002-2006).
SETTINGS - This population-based study was conducted in urban Shanghai, China.
PARTICIPANTS - A total of 217 incident liver cancer cases diagnosed through 31 December 2009 and 427 healthy controls matched by sex, age at baseline (±2 years) and date (±30 days) of sample collection were included in the study.
PRIMARY AND SECONDARY OUTCOME MEASURES - Genetic polymorphisms of NFKB1 and NFKBIA were determined blindly by TaqMan single-nucleotide polymorphism (SNP) genotyping assay. OR and its 95% CIs were estimated by an unconditional logistic regression model to measure the association between selected SNPs and the risk of liver cancer.
RESULTS - After adjusted for potential confounding factors, rs28362491 ins/del or del/del genotypes were associated with higher risk of liver cancer with an adjusted OR 1.54 (95% CI 1.04 to 2.28). rs230496 AG and GG genotypes were also noted with higher risk of liver cancer with an adjusted OR 1.53 (95% CI 1.03 to 2.26). Haplotype analysis indicated that carriers of the NFKB1 GA and AA (rs230525-rs230530) haplotypes had higher risk of liver cancer under an additive model. No association was observed between NFKBIA variants and risk of live cancer.
CONCLUSIONS - Our results suggest that genetic variants of NFKB1 influence liver cancer susceptibility in Chinese population, although replication in other studies is needed.
0 Communities
2 Members
0 Resources
16 MeSH Terms
Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling.
Edwards JR, Perrien DS, Fleming N, Nyman JS, Ono K, Connelly L, Moore MM, Lwin ST, Yull FE, Mundy GR, Elefteriou F
(2013) J Bone Miner Res 28: 960-9
MeSH Terms: Acetylation, Aging, Animals, Bone Remodeling, Bone and Bones, Gene Deletion, Gene Knockdown Techniques, I-kappa B Proteins, Mice, NF-KappaB Inhibitor alpha, NF-kappa B, Organ Size, Organ Specificity, Osteoblasts, Osteoclasts, Signal Transduction, Sirtuin 1
Show Abstract · Added November 14, 2013
Silent information regulator T1 (SirT1) is linked to longevity and negatively controls NF-κB signaling, a crucial mediator of survival and regulator of both osteoclasts and osteoblasts. Here we show that NF-κB repression by SirT1 in both osteoclasts and osteoblasts is necessary for proper bone remodeling and may contribute to the mechanisms linking aging and bone loss. Osteoclast- or osteoblast-specific SirT1 deletion using the Sirt(flox/flox) mice crossed to lysozyme M-cre and the 2.3 kb col1a1-cre transgenic mice, respectively, resulted in decreased bone mass caused by increased resorption and reduced bone formation. In osteoclasts, lack of SirT1 promoted osteoclastogenesis in vitro and activated NF-κB by increasing acetylation of Lysine 310. Importantly, this increase in osteoclastogenesis was blocked by pharmacological inhibition of NF-κB. In osteoblasts, decreased SirT1 reduced osteoblast differentiation, which could also be rescued by inhibition of NF-κB. In further support of the critical role of NF-κB signaling in bone remodeling, elevated NF-κB activity in IκBα(+/-) mice uncoupled bone resorption and formation, leading to reduced bone mass. These findings support the notion that SirT1 is a genetic determinant of bone mass, acting in a cell-autonomous manner in both osteoblasts and osteoclasts, through control of NF-κB and bone cell differentiation.
Copyright © 2013 American Society for Bone and Mineral Research.
2 Communities
5 Members
0 Resources
17 MeSH Terms
Lysine392, a K63-linked ubiquitination site in NEMO, mediates inflammatory osteoclastogenesis and osteolysis.
Alhawagri M, Yamanaka Y, Ballard D, Oltz E, Abu-Amer Y
(2012) J Orthop Res 30: 554-60
MeSH Terms: Animals, Bone Resorption, Extracellular Signal-Regulated MAP Kinases, Germ-Line Mutation, I-kappa B Proteins, Intracellular Signaling Peptides and Proteins, JNK Mitogen-Activated Protein Kinases, Lysine, Mice, Mice, Mutant Strains, Mutagenesis, Site-Directed, Osteitis, Osteoclasts, Osteolysis, Polymethyl Methacrylate, Prosthesis Failure, Signal Transduction, Ubiquitination, p38 Mitogen-Activated Protein Kinases
Show Abstract · Added January 10, 2014
PMMA particles released from bone implants are considered major contributor to osteolysis and subsequent implant failure. Although the ensuing inflammatory response has been described, the mechanisms underlying PMMA particulate-induced osteolysis remain enigmatic. In previous studies, we have established that activation of Nuclear factor kappa-B (NF-κB) and MAP kinase pathways plays a central role in the pathogenesis of inflammatory osteolysis. Specifically, we have shown that impeding IKK complex assembly, and thus subsequent NF-κB activation, dampens particle-induced osteolysis. The IKK complex consists of IKKα, IKKβ, and IKKγ, also known as NEMO. NEMO has no catalytic activity and serves as a scaffold protein facilitating assembly and distal activation of NF-κB signaling. In fact, blocking binding of NEMO with IKKα/β abolishes NF-κB activity. In the current study, we identify Lysine 392 residue in NEMO as crucial mediator of PMMA particle-induced inflammatory osteoclastogenesis and osteolysis. Using mice in which NEMO-K392R mutation has been introduced, we provide evidence that PMMA-induced osteoclasts and osteolytic responses are impaired. Furthermore, we show that this impairment is likely due to poor activation of NF-κB and Erk, but not other MAP kinases. Our findings suggest that NEMO Lysine392, a well-established K63-linked polyubiquitination site, is an important mediator of PMMA-induced osteolysis. Therefore, this NEMO motif should be considered as a target to combat PMMA particle-induced osteolysis.
Copyright © 2011 Orthopaedic Research Society.
1 Communities
0 Members
0 Resources
19 MeSH Terms
Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans.
Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, Washington MK, Kokoye Y, Crowe SE, Zaika A, Correa P, Peek RM, El-Rifai W
(2011) J Clin Invest 121: 1753-67
MeSH Terms: Animals, Disease Progression, Gastric Mucosa, Gene Expression Profiling, Humans, I-kappa B Proteins, Inflammation, Mice, Mice, Inbred C57BL, Mice, Knockout, NF-KappaB Inhibitor alpha, NF-kappa B, Oligonucleotide Array Sequence Analysis, Peptides, Phosphorylation, Stomach Neoplasms, Trefoil Factor-1, Tumor Necrosis Factor-alpha, Tumor Suppressor Proteins
Show Abstract · Added July 26, 2012
Trefoil factor 1 (TFF1) is a tumor suppressor gene that encodes a peptide belonging to the trefoil factor family of protease-resistant peptides. Although TFF1 expression is frequently lost in gastric carcinomas, the tumorigenic pathways this affects have not been determined. Here we show that Tff1-knockout mice exhibit age-dependent carcinogenic histological changes in the pyloric antrum of the gastric mucosa, progressing from gastritis to hyperplasia, low-grade dysplasia, high-grade dysplasia, and ultimately malignant adenocarcinoma. The histology and molecular signatures of gastric lesions in the Tff1-knockout mice were consistent with an inflammatory phenotype. In vivo, ex-vivo, and in vitro studies showed that TFF1 expression suppressed TNF-α-mediated NF-κB activation through the TNF receptor 1 (TNFR1)/IκB kinase (IKK) pathway. Consistent with these mouse data, human gastric tissue samples displayed a progressive decrease in TFF1 expression and an increase in NF-κB activation along the multi-step carcinogenesis cascade. Collectively, these results provide evidence that loss of TFF1 leads to activation of IKK complex-regulated NF-κB transcription factors and is an important event in shaping the NF-κB-mediated inflammatory response during the progression to gastric tumorigenesis.
1 Communities
6 Members
0 Resources
19 MeSH Terms
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL
(2011) Nature 471: 523-6
MeSH Terms: Cell Line, Tumor, Dose-Response Relationship, Drug, Down-Regulation, Drug Resistance, Neoplasm, ErbB Receptors, Erlotinib Hydrochloride, Genes, erbB-1, Humans, I-kappa B Proteins, Lung Neoplasms, Models, Biological, Mutant Proteins, Mutation, NF-kappa B, Quinazolines, RNA Interference, Signal Transduction, fas Receptor
Show Abstract · Added May 27, 2014
Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient. This heterogeneity in treatment response could result from genetic modifiers that regulate the degree to which tumour cells are dependent on mutant EGFR. Through a pooled RNA interference screen, we show that knockdown of FAS and several components of the NF-κB pathway specifically enhanced cell death induced by the EGFR TKI erlotinib in EGFR-mutant lung cancer cells. Activation of NF-κB through overexpression of c-FLIP or IKK (also known as CFLAR and IKBKB, respectively), or silencing of IκB (also known as NFKBIA), rescued EGFR-mutant lung cancer cells from EGFR TKI treatment. Genetic or pharmacologic inhibition of NF-κB enhanced erlotinib-induced apoptosis in erlotinib-sensitive and erlotinib-resistant EGFR-mutant lung cancer models. Increased expression of the NF-κB inhibitor IκB predicted for improved response and survival in EGFR-mutant lung cancer patients treated with EGFR TKI. These data identify NF-κB as a potential companion drug target, together with EGFR, in EGFR-mutant lung cancers and provide insight into the mechanisms by which tumour cells escape from oncogene dependence.
0 Communities
1 Members
0 Resources
18 MeSH Terms
NFKBIA deletion in glioblastomas.
Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR
(2011) N Engl J Med 364: 627-37
MeSH Terms: DNA Mutational Analysis, Gene Amplification, Gene Deletion, Gene Expression, Genes, erbB-1, Glioblastoma, Humans, I-kappa B Proteins, Kaplan-Meier Estimate, NF-KappaB Inhibitor alpha, Prognosis, Tumor Cells, Cultured
Show Abstract · Added August 14, 2014
BACKGROUND - Amplification and activating mutations of the epidermal growth factor receptor (EGFR) oncogene are molecular hallmarks of glioblastomas. We hypothesized that deletion of NFKBIA (encoding nuclear factor of κ-light polypeptide gene enhancer in B-cells inhibitor-α), an inhibitor of the EGFR-signaling pathway, promotes tumorigenesis in glioblastomas that do not have alterations of EGFR.
METHODS - We analyzed 790 human glioblastomas for deletions, mutations, or expression of NFKBIA and EGFR. We studied the tumor-suppressor activity of NFKBIA in tumor-cell culture. We compared the molecular results with the outcome of glioblastoma in 570 affected persons.
RESULTS - NFKBIA is often deleted but not mutated in glioblastomas; most deletions occur in nonclassical subtypes of the disease. Deletion of NFKBIA and amplification of EGFR show a pattern of mutual exclusivity. Restoration of the expression of NFKBIA attenuated the malignant phenotype and increased the vulnerability to chemotherapy of cells cultured from tumors with NFKBIA deletion; it also reduced the viability of cells with EGFR amplification but not of cells with normal gene dosages of both NFKBIA and EGFR. Deletion and low expression of NFKBIA were associated with unfavorable outcomes. Patients who had tumors with NFKBIA deletion had outcomes that were similar to those in patients with tumors harboring EGFR amplification. These outcomes were poor as compared with the outcomes in patients with tumors that had normal gene dosages of NFKBIA and EGFR. A two-gene model that was based on expression of NFKBIA and O(6)-methylguanine DNA methyltransferase was strongly associated with the clinical course of the disease.
CONCLUSIONS - Deletion of NFKBIA has an effect that is similar to the effect of EGFR amplification in the pathogenesis of glioblastoma and is associated with comparatively short survival.
0 Communities
1 Members
0 Resources
12 MeSH Terms
Analysis of SRrp86-regulated alternative splicing: control of c-Jun and IκBβ activity.
Solis AS, Patton JG
(2010) RNA Biol 7: 486-94
MeSH Terms: Alternative Splicing, Animals, Cell Line, Tumor, HeLa Cells, Humans, I-kappa B Proteins, Microarray Analysis, NF-kappa B, Nuclear Proteins, Proto-Oncogene Proteins c-jun, RNA Splicing, RNA-Binding Proteins, Rats, Serine-Arginine Splicing Factors
Show Abstract · Added May 27, 2014
Previous work led to the hypothesis that SRrp86, a related member of the SR protein superfamily, can interact with and modulate the activity of other SR proteins. Here, we sought to test this hypothesis by examining the effect of changing SRrp86 concentrations on overall alternative splicing patterns. SpliceArrays were used to examine 9,854 splicing events in wild-type cells, cells overexpressing SRrp86, and cells treated with siRNAs to knockdown SRrp86. From among the 500 splicing events exhibiting altered splicing under these conditions, the splicing of c-Jun and IκBβ were validated as being regulated by SRrp86 resulting in altered regulation of their downstream targets. In both cases, functionally distinct isoforms were generated that demonstrate the role SRrp86 plays in controlling alternative splicing.
0 Communities
1 Members
0 Resources
14 MeSH Terms
Myeloid cells control termination of lung inflammation through the NF-kappaB pathway.
Han W, Joo M, Everhart MB, Christman JW, Yull FE, Blackwell TS
(2009) Am J Physiol Lung Cell Mol Physiol 296: L320-7
MeSH Terms: Animals, Cell Line, Chemokines, CXC, Coculture Techniques, Female, Humans, I-kappa B Proteins, Lipopolysaccharides, Macrophages, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Myeloid Cells, NF-KappaB Inhibitor alpha, NF-kappa B, NF-kappa B p50 Subunit, Neutrophils, Pneumonia, Transplantation Chimera
Show Abstract · Added February 26, 2013
Although acute lung inflammation in response to local or systemic infection involves myeloid and nonmyeloid cells, the interplay between different cell types remains poorly defined. Since NF-kappaB is a key transcription factor for innate immunity, we investigated whether dysregulated NF-kappaB activation in myeloid cells impacts inflammatory signaling in nonmyeloid cells and generation of neutrophilic lung inflammation in response to systemic endotoxemia. We generated bone marrow chimeras by fetal liver transplantation of cells deficient in IkappaBalpha or p50 into lethally irradiated NF-kappaB reporter transgenic mice. No differences were apparent between bone marrow chimeras in the absence of an inflammatory stimulus; however, following intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS), IkappaBalpha- or p50-deficient bone marrow chimeras showed increased NF-kappaB activation in nonhematopoietic cells, exaggerated neutrophilic inflammation, and higher mortality compared with untransplanted reporter mice and wild-type bone marrow chimeras. Primary bone marrow-derived macrophages (BMDM) from IkappaBalpha(-/-) or p50(-/-) exhibited increased NF-kappaB activation and macrophage inflammatory protein-2 production after LPS treatment compared with wild-type cells, and coculture of BMDM with lung epithelial (A549) cells resulted in increased NF-kappaB activation in A549 cells and excess IL-8 production by these epithelial cells. These studies indicate an important role for inhibitory members of the NF-kappaB family acting specifically within myeloid cells to limit inflammatory responses in the lungs.
2 Communities
2 Members
0 Resources
21 MeSH Terms
Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2.
Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, Fesik SW, Sun Y
(2008) Cancer Res 68: 7570-8
MeSH Terms: Animals, Apoptosis, Carcinoma, Non-Small-Cell Lung, Cell Cycle Proteins, Cell Division, Cell Growth Processes, Cell Line, Tumor, G2 Phase, Gene Silencing, Glioblastoma, Humans, I-kappa B Proteins, Lung Neoplasms, Mice, NF-KappaB Inhibitor alpha, NF-kappa B, Nuclear Pore Complex Proteins, RNA, Small Interfering, RNA-Binding Proteins, Radiation Tolerance, TNF Receptor-Associated Factor 2
Show Abstract · Added March 5, 2014
Radiotherapy combined with chemotherapy is the treatment of choice for glioblastoma and locally advanced lung cancer, but radioresistance of these two types of cancer remains a significant therapeutic hindrance. To identify molecular target(s) for radiosensitization, we screened a small interfering RNA (siRNA) library targeting all protein kinases and E3 ubiquitin ligases in the human genome and identified tumor necrosis factor receptor-associated factor 2 (TRAF2). Silencing of TRAF2 using siRNA caused a significant growth suppression of glioblastoma U251 cells and moderately sensitized these radioresistant cells to radiation. Overexpression of a really interesting new gene (RING)-deleted dominant-negative TRAF2 mutant also conferred radiosensitivity, whereas overexpression of wild-type (WT) TRAF2 significantly protected cells from radiation-induced killing. Likewise, siRNA silencing of TRAF2 in radioresistant lung cancer H1299 cells caused growth suppression and radiosensitization, whereas overexpression of WT TRAF2 enhanced radioresistance in a RING ligase-dependent manner. Moreover, siRNA silencing of TRAF2 in UM-SCC-1 head and neck cancer cells also conferred radiosensitization. Further support for the role of TRAF2 in cancer comes from the observations that TRAF2 is overexpressed in both lung adenocarcinoma tissues and multiple lung cancer cell lines. Importantly, TRAF2 expression was very low in normal bronchial epithelial NL20 cells, and TRAF2 silencing had a minimal effect on NL20 growth and radiation sensitivity. Mechanistically, TRAF2 silencing blocks the activation of the nuclear factor-kappaB signaling pathway and down-regulates several G(2)-M cell cycle control proteins, resulting in enhanced G(2)-M arrest, growth suppression, and radiosensitization. Our studies suggest that TRAF2 is an attractive drug target for anticancer therapy and radiosensitization.
0 Communities
1 Members
0 Resources
21 MeSH Terms